eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

Conditions

• Pulmonary Disease, Chronic Obstructive

Eligibility Criteria

Sex

ALL

Age

40 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Depemokimab — DRUG
  Depemokimab will be administered.
• Placebo — DRUG
  Matching placebo will be administered.

Study Details

Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

Key Dates

First listed

Sep 17, 2025

Start date

Oct 20, 2025

Status verified

Jul 2026

Primary completion

Apr 30, 2029

Completion

Jun 8, 2029

Study Design

Enrollment

1,196 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Depemokimab
  Participants with Chronic Obstructive Pulmonary Disorder (COPD) with Type 2 inflammation will receive Depemokimab in combination with existing Standard of Care (SoC).
• Experimental: Placebo
  Participants with COPD with Type 2 inflammation will receive matching Placebo in combination with existing SoC.

Primary Outcome Measure

Annualized Rate of Moderate/Severe Exacerbations [ Time Frame: From Baseline Up to Week 156 ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (42)

Find similar trials in Newport Beach, CA

Related Studies

• A Study of the Effect of a Nurse Navigator Program on High Risk Patients
  Not Yet Recruiting · Mayo Clinic · Jacksonville, Florida
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
  PHASE3 · Recruiting · GlaxoSmithKline · Loxahatchee Groves, Florida
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
  PHASE3 · Recruiting · GlaxoSmithKline · Sheffield, Alabama
• Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD
  Enrolling By Invitation · VA Office of Research and Development · Phoenix, Arizona